[{"id":780,"uid":"NPDI-f1iDGA","name":"Clinical Pharmacokinetic Assessment of Kratom (Mitragyna speciosa), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants","napdiIdentifier":null,"overallSummary":"Increasing use of the botanical kratom to self-manage opioid withdrawal and pain has led to increased kratom-linked overdose deaths. Despite these serious safety concerns, rigorous fundamental pharmacokinetic knowledge of kratom in humans remains lacking. We assessed the pharmacokinetics of a single low dose (2 g) of a well-characterized kratom product administered orally to six healthy participants. Median concentration-time profiles for the kratom alkaloids examined were best described by a two-compartment model with central elimination. Pronounced pharmacokinetic differences between alkaloids with the 3<em>S</em> configuration (mitragynine, speciogynine, paynantheine) and alkaloids with the 3<em>R</em> configuration (mitraciliatine, speciociliatine, isopaynantheine) were attributed to differences in apparent intercompartmental distribution clearance, volumes of distribution, and clearance. Based on noncompartmental analysis of individual concentration-time profiles, the 3<em>S</em> alkaloids exhibited a shorter median time to maximum concentration (1-2 vs. 2.5-4.5 h), lower area under the plasma concentration-time curve (430-490 vs. 794-5120 nM × h), longer terminal half-life (24-45 vs. ~12-18 h), and higher apparent volume of distribution during the terminal phase (960-12,700 vs. ~46-130 L) compared to the 3<em>R</em> alkaloids. Follow-up mechanistic in vitro studies suggested differential hepatic/intestinal metabolism, plasma protein binding, blood-to-plasma partitioning, and/or distribution coefficients may explain the pharmacokinetic differences between the two alkaloid types. This first comprehensive pharmacokinetic characterization of kratom alkaloids in humans provides the foundation for further research to establish safety and effectiveness of this emerging botanical product.","pubmedId":35335999,"embaseId":null,"croIdentifier":"WSU-1","croInformation":"Department of Pharmaceutical Sciences, Washington State University","dateStart":null,"dateEnd":null,"internalComment":null,"status":"published","compoundId":null,"naturalProductUid":"NP-00ed1235-cbd8-4117-85df-298b8b3cdcad","naturalProductSampleId":null,"studySourceTypeId":1,"naturalProduct":{"uid":"NP-00ed1235-cbd8-4117-85df-298b8b3cdcad","binomial":"Mitragyna speciosa","name":"Kratom","itis":null,"srs":"d469b67d-e9a6-459f-b209-c59451936336","source_id":"","conceptId":null},"compound":null,"studySourceType":{"id":1,"name":"Published report"},"experiments":[{"id":1070,"uid":"NPDI-pX3CPg","name":"paynantheine","overallEffect":0,"isControlData":false,"isIc50Shift":false,"croCutoff":null,"croIdentifier":"WSU-paynantheine","comment":null,"experimentalConditionsComment":null,"resultsComment":"These values are based on the two-compartment model with elimination rate used to describe the median concentration-time profiles of all kratom alkaloids. Data from 5 healthy adults who completed the study (out of 7 enrolled) was used to calculate the results.​","internalComment":null,"objectCompoundId":null,"objectMetaboliteCompoundId":null,"precipitantCompoundId":null,"cytochromeB5Id":null,"studyId":780,"experimentTypeId":8,"testSystemId":null,"ic50ShiftExperimentId":null,"controlDataExperimentId":null,"controlDataForExperimentId":null,"naturalProductSampleId":null,"experimentType":{"id":8,"name":"In Vivo Pharmacokinetics","isInVitro":false,"isTransporter":false,"isEnzyme":false,"purl":"http://purl.obolibrary.org/obo/DIDEO_00000075"},"objectCompound":null,"precipitantCompound":null,"objectMetaboliteCompound":null,"enzymes":[],"transporters":[],"quantifiedMetabolites":[]},{"id":1069,"uid":"NPDI-p8vUgQ","name":"speciociliatine","overallEffect":0,"isControlData":false,"isIc50Shift":false,"croCutoff":null,"croIdentifier":"WSU-speciociliatine","comment":null,"experimentalConditionsComment":null,"resultsComment":"These values are based on the two-compartment model with elimination rate used to describe the median concentration-time profiles of all kratom alkaloids. Data from 5 healthy adults who completed the study (out of 7 enrolled) was used to calculate the results.","internalComment":null,"objectCompoundId":null,"objectMetaboliteCompoundId":null,"precipitantCompoundId":null,"cytochromeB5Id":null,"studyId":780,"experimentTypeId":8,"testSystemId":null,"ic50ShiftExperimentId":null,"controlDataExperimentId":null,"controlDataForExperimentId":null,"naturalProductSampleId":null,"experimentType":{"id":8,"name":"In Vivo Pharmacokinetics","isInVitro":false,"isTransporter":false,"isEnzyme":false,"purl":"http://purl.obolibrary.org/obo/DIDEO_00000075"},"objectCompound":null,"precipitantCompound":null,"objectMetaboliteCompound":null,"enzymes":[],"transporters":[],"quantifiedMetabolites":[]},{"id":1071,"uid":"NPDI-c1a6PQ","name":"isopaynantheine","overallEffect":0,"isControlData":false,"isIc50Shift":false,"croCutoff":null,"croIdentifier":"WSU-isopaynantheine","comment":null,"experimentalConditionsComment":null,"resultsComment":"These values are based on the two-compartment model with elimination rate used to describe the median concentration-time profiles of all kratom alkaloids. Data from 5 healthy adults who completed the study (out of 7 enrolled) was used to calculate the results.","internalComment":null,"objectCompoundId":null,"objectMetaboliteCompoundId":null,"precipitantCompoundId":null,"cytochromeB5Id":null,"studyId":780,"experimentTypeId":8,"testSystemId":null,"ic50ShiftExperimentId":null,"controlDataExperimentId":null,"controlDataForExperimentId":null,"naturalProductSampleId":null,"experimentType":{"id":8,"name":"In Vivo Pharmacokinetics","isInVitro":false,"isTransporter":false,"isEnzyme":false,"purl":"http://purl.obolibrary.org/obo/DIDEO_00000075"},"objectCompound":null,"precipitantCompound":null,"objectMetaboliteCompound":null,"enzymes":[],"transporters":[],"quantifiedMetabolites":[]},{"id":1067,"uid":"NPDI-RfQQdQ","name":"speciogynine","overallEffect":0,"isControlData":false,"isIc50Shift":false,"croCutoff":null,"croIdentifier":"WSU-speciogynine","comment":null,"experimentalConditionsComment":null,"resultsComment":"Data from 5 healthy adults who completed the study (out of 7 enrolled) was used to calculate the results using compartmental model-derived pharmacokinetic estimates. ​","internalComment":null,"objectCompoundId":null,"objectMetaboliteCompoundId":null,"precipitantCompoundId":null,"cytochromeB5Id":null,"studyId":780,"experimentTypeId":8,"testSystemId":null,"ic50ShiftExperimentId":null,"controlDataExperimentId":null,"controlDataForExperimentId":null,"naturalProductSampleId":null,"experimentType":{"id":8,"name":"In Vivo Pharmacokinetics","isInVitro":false,"isTransporter":false,"isEnzyme":false,"purl":"http://purl.obolibrary.org/obo/DIDEO_00000075"},"objectCompound":null,"precipitantCompound":null,"objectMetaboliteCompound":null,"enzymes":[],"transporters":[],"quantifiedMetabolites":[]},{"id":1066,"uid":"NPDI-PsV3FA","name":"mitragynine","overallEffect":0,"isControlData":false,"isIc50Shift":false,"croCutoff":null,"croIdentifier":"WSU-mitragynine","comment":null,"experimentalConditionsComment":null,"resultsComment":"Data from 5 healthy adults who completed the study (out of 7 enrolled) was used to calculate the compartmental model-derived pharmacokinetic estimates.","internalComment":null,"objectCompoundId":null,"objectMetaboliteCompoundId":null,"precipitantCompoundId":null,"cytochromeB5Id":null,"studyId":780,"experimentTypeId":8,"testSystemId":null,"ic50ShiftExperimentId":null,"controlDataExperimentId":null,"controlDataForExperimentId":null,"naturalProductSampleId":null,"experimentType":{"id":8,"name":"In Vivo Pharmacokinetics","isInVitro":false,"isTransporter":false,"isEnzyme":false,"purl":"http://purl.obolibrary.org/obo/DIDEO_00000075"},"objectCompound":null,"precipitantCompound":null,"objectMetaboliteCompound":null,"enzymes":[],"transporters":[],"quantifiedMetabolites":[]},{"id":1068,"uid":"NPDI-y7NNJA","name":"mitraciliatine","overallEffect":0,"isControlData":false,"isIc50Shift":false,"croCutoff":null,"croIdentifier":"WSU-mitraciliatine","comment":null,"experimentalConditionsComment":null,"resultsComment":"Data from 5 healthy adults who completed the study (out of 7 enrolled) was used to calculate the results using compartmental model-derived pharmacokinetic estimates .","internalComment":null,"objectCompoundId":null,"objectMetaboliteCompoundId":null,"precipitantCompoundId":null,"cytochromeB5Id":null,"studyId":780,"experimentTypeId":8,"testSystemId":null,"ic50ShiftExperimentId":null,"controlDataExperimentId":null,"controlDataForExperimentId":null,"naturalProductSampleId":null,"experimentType":{"id":8,"name":"In Vivo Pharmacokinetics","isInVitro":false,"isTransporter":false,"isEnzyme":false,"purl":"http://purl.obolibrary.org/obo/DIDEO_00000075"},"objectCompound":null,"precipitantCompound":null,"objectMetaboliteCompound":null,"enzymes":[],"transporters":[],"quantifiedMetabolites":[]}]}]